Malik P - Search Results

1

The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges.

Goodman MA, Malik P. Goodman MA, et al. Among authors: malik p. Ther Adv Hematol. 2016 Oct;7(5):302-315. doi: 10.1177/2040620716653729. Epub 2016 Jun 25. Ther Adv Hematol. 2016. PMID: 27695619 Free PMC article. Review.

2

Gene therapy for hemoglobinopathies: the state of the field and the future.

Chandrakasan S, Malik P. Chandrakasan S, et al. Among authors: malik p. Hematol Oncol Clin North Am. 2014 Apr;28(2):199-216. doi: 10.1016/j.hoc.2013.12.003. Hematol Oncol Clin North Am. 2014. PMID: 24589262 Free PMC article. Review.

3

CRISPR/Cas9 in allergic and immunologic diseases.

Goodman MA, Moradi Manesh D, Malik P, Rothenberg ME. Goodman MA, et al. Among authors: malik p. Expert Rev Clin Immunol. 2017 Jan;13(1):5-9. doi: 10.1080/1744666X.2017.1241711. Epub 2016 Oct 24. Expert Rev Clin Immunol. 2017. PMID: 27687572 Free PMC article. No abstract available.

4

Patient Perspectives on Gene Transfer Therapy for Sickle Cell Disease.

Strong H, Mitchell MJ, Goldstein-Leever A, Shook L, Malik P, Crosby LE. Strong H, et al. Among authors: malik p. Adv Ther. 2017 Aug;34(8):2007-2021. doi: 10.1007/s12325-017-0587-7. Epub 2017 Jul 17. Adv Ther. 2017. PMID: 28717861 Free PMC article.

5

Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential.

Goodman MA, Arumugam P, Pillis DM, Loberg A, Nasimuzzaman M, Lynn D, van der Loo JCM, Dexheimer PJ, Keddache M, Bauer TR Jr, Hickstein DD, Russell DW, Malik P. Goodman MA, et al. Among authors: malik p. J Virol. 2017 Dec 14;92(1):e01639-17. doi: 10.1128/JVI.01639-17. Print 2018 Jan 1. J Virol. 2017. PMID: 29046446 Free PMC article.

6

CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites.

Jayavaradhan R, Pillis DM, Goodman M, Zhang F, Zhang Y, Andreassen PR, Malik P. Jayavaradhan R, et al. Among authors: malik p. Nat Commun. 2019 Jun 28;10(1):2866. doi: 10.1038/s41467-019-10735-7. Nat Commun. 2019. PMID: 31253785 Free PMC article.

7

Gene therapy for hemoglobinopathies: are we there yet?

Puthenveetil G, Malik P. Puthenveetil G, et al. Among authors: malik p. Curr Hematol Rep. 2004 Jul;3(4):298-305. Curr Hematol Rep. 2004. PMID: 15217560 Review.

8

Genetic therapy for beta-thalassemia: from the bench to the bedside.

Arumugam P, Malik P. Arumugam P, et al. Among authors: malik p. Hematology Am Soc Hematol Educ Program. 2010;2010:445-50. doi: 10.1182/asheducation-2010.1.445. Hematology Am Soc Hematol Educ Program. 2010. PMID: 21239833

9

Biomarkers for early detection of sickle nephropathy.

Sundaram N, Bennett M, Wilhelm J, Kim MO, Atweh G, Devarajan P, Malik P. Sundaram N, et al. Among authors: malik p. Am J Hematol. 2011 Jul;86(7):559-66. doi: 10.1002/ajh.22045. Epub 2011 May 31. Am J Hematol. 2011. PMID: 21630304 Free PMC article. Clinical Trial.

10

Pigtailed macaques as a model to study long-term safety of lentivirus vector-mediated gene therapy for hemoglobinopathies.

Kiem HP, Arumugam PI, Burtner CR, Fox CF, Beard BC, Dexheimer P, Adair JE, Malik P. Kiem HP, et al. Among authors: malik p. Mol Ther Methods Clin Dev. 2014 Dec 17;1:14055. doi: 10.1038/mtm.2014.55. eCollection 2014. Mol Ther Methods Clin Dev. 2014. PMID: 26052523 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

785 results

Search Page